Previous 10 | Next 10 |
MALVERN, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced panel participation in the International Conference on Alzheimer’s and Parkinson’...
MALVERN, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last patient last visit in the phase II/III study of its lead candidate buntanetap in patients w...
2024-02-12 09:06:20 ET Summary A small sample of patient anecdotes on the internet suggest that buntanetap has some degree of underlying activity in Parkinson’s disease (PD). 24-38% of patient anecdotes report a noticeable/measurable improvement in Parkinson’s sympto...
2024-02-01 16:10:53 ET More on Annovis Bio Annovis And Alzheimer's Disease: The Best-Laid Plans Stocks To Watch: Eyes On Chipmakers, Tesla, Netflix And BrightSpring IPO Annovis Bio: Buntanetap Likely To Disappoint In The Upcoming AD And PD Clinical Trials Ann...
MALVERN, Pa., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the filing of a patent application covering the use of buntanetap and its analogues for the treatment of neur...
2024-01-29 23:44:21 ET Summary Annovis will likely announce results from it Parkinson's disease and Alzheimer's disease trials in the next couple of month. Annovis inhibits the formation of the amyloid precursor protein. The primary triggers for Alzheimer's disease are unrelat...
2024-01-24 12:48:28 ET More on Mid-day movers $ stocks. Peraso Inc. (PRSO) Q3 2023 Earnings Call Transcript Sight Sciences, Inc. (SGHT) Q3 2023 Earnings Call Transcript Curis, Inc. (CRIS) Q3 2023 Earnings Call Transcript Sight Sciences says Q4 total revenue i...
2024-01-24 11:30:45 ET More on Annovis Bio Stocks To Watch: Eyes On Chipmakers, Tesla, Netflix And BrightSpring IPO Annovis Bio: Buntanetap Likely To Disappoint In The Upcoming AD And PD Clinical Trials Annovis Bio gains after enrollment update on trial for Alzheimer...
2024-01-24 10:01:06 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Investors were most bullish on H...
2024-01-24 08:40:30 ET Losers: Theratechnologies THTX -30% says FDA rejected new Egrifta version . Annovis Bio ( ANVS ) -11% refines timeline for Parkinson’s phase III study data announcement . BlackBerry Ltd BB -11% announces proposed private ...
News, Short Squeeze, Breakout and More Instantly...
Annovis Bio Inc. Company Name:
ANVS Stock Symbol:
OTCMKTS Market:
A look at the top 10 most actives in the United States Next.e.GO N.V. (EGOX) rose 38.0% to $0.0381 on volume of 59,468,925 shares Greenwave Technology Solutions Inc. (GWAV) rose 1.5% to $0.066 on volume of 45,683,331 shares Global Mofy Metaverse Limited (GMM) rose 68.4% to $1.5667 on volu...
2024-04-30 09:00:04 ET Sumant Kulkarni from Canaccord Genuity issued a price target of $26.00 for ANVS on 2024-04-30 07:34:00. The adjusted price target was set to $26.00. At the time of the announcement, ANVS was trading at $7.28. ANVS currently trades -67.60% versus it...
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 0.1% on Monday. The Dow traded up 0.19% to 38,313.56 ...